Related Content
- Pfizer forms licensing agreement with Seattle Genetics
- Matrix Labs' gabapentin capsules get FDA OK
- Hi-Tech Pharmacal receives market exclusivity for generic Neurontin
- FDA approves Novartis drug for high blood pressure treatment
- Walgreens puts its money where its mouth is with World AIDS Day campaign
MENLO PARK, Calif. — Depomed has launched a new drug for treating shingles, the drug maker said Monday.
The company announced the launch of Gralise (gabapentin) tablets, a once-daily treatment for postherpetic neuralgia, the pain that follows healing of the rash associated with shingles.
Gralise is a proprietary formulation of gabapentin that uses patented polymer technology that enables gradual release of the drug. Depomed said it is not interchangeable with other branded or generic gabapentin-based drugs.
Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.
